Bringing The Next-Generation Of Antibiotics
to win the war against resistant bacteria
Our Vision
Our company
Omnix Medical is a biopharmaceutical company
Founded in 2015, Omnix Medical is developing an arsenal of novel antibiotic agents for the treatment of infections involving drug-resistant bacteria.
Omnix’s technology can tilt the odds in the battle against resistant bacteria and improve the lives of many people worldwide.
Our technology
Our exceptional technology offers a first-in-its-class drug
Company News
Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials
“Antibacterial agents active against Gram‑Negative Bacilli in Phase I, II, or III Clinical Trials,” by David L. Paterson, surveys nearly 50 investigational therapeutics—28 small‑molecule antibiotics and 21 non‑traditional modalities—now in the clinic. The review highlights
Outstanding Scientific Research Award for Omnix Medical’s novel OMN51
We’re thrilled to share that Omnix Medical’s research, in collaboration with Dr. Heching, the Adult Cystic Fibrosis and Bronchiectasis Clinic Director at Beilinson-Rabin Medical Center,
Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6
Designation underlines the need for novel, first-in-class antimicrobials for the treatment of infections with Gram-negative bacteria Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No 966627 (OMNIX MEDICAL).